Entering text into the input field will update the search result below

Eli Lilly hits new all-time high buoyed by recent drug approvals; up 21% YTD

Jul. 06, 2022 11:00 AM ETEli Lilly and Company (LLY) StockBy: Jonathan Block, SA News Editor7 Comments

Indianapolis - April 2016: Eli Lilly and Company VI

jetcityimage/iStock Editorial via Getty Images

  • Eli Lilly (NYSE:LLY), already one of the best performing large pharma stocks year to date, hit an all-time high of $332.74 on Wednesday morning.
  • YTD, the stock is up 21%.
  • In what may end up

Recommended For You

Comments (7)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Tirzepatide is the most amazing product for Diabetes and Obesity.
It is taken once a week . A sub-Q injection that is self administered with a pen.
peak sales will exceed $10 Billion.
Good job LLY.
People will pay up for fat pills when they work, and this one seems to work very very well!
so, apparently you can teach an old dog new tricks! Good on Lilly!
SuperPac profile picture
For long, I have been asking readers to view the LLY stock constructively and invest on declines for the long haul. Now, it's run up so much and the valuation seems so rich. I wish to add more but can't at this level. May be I will come to regret my decision when it goes even higher from here.
There is always a price where even the best stocks are fundamentally expensive. Paying up for future growth is the story here and we have seen way too many times what can happen when the perception of the market shifts. Even the behemoths of tech industry (AAPL, AMZN, FB, NFLX, GOOG) have struggled mightily of late. Better to maintain buying discipline when valuations get stretched on the upside. Momentum can shift and take the froth out in a jiffy.
bill h illify profile picture
This has been a good one for me.
Oldie but goodie!

About LLY Stock

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Eli Lilly and Company
Johnson & Johnson
Merck & Co., Inc.
Roche Holding AG
AstraZeneca PLC
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.